See the answer from Francois Nader, chairman of Acceleron Pharma.
See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital.
See the answer from Joe Ferra, CFO of Syros Pharmaceuticals.
See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.
See the answer from John Crowley, the Chairman & CEO of Amicus Therapeutics, a global biotech focused on developing medicines for people living with rare diseases.
See the answer from Martin Lehr, CEO and cofounder at Context Therapeutics, a clinical-stage biopharma dedicated to developing novel medicines for hormone receptor positive cancers.
See the answer from Jason Urban, Ph.D., who heads up Alexion Pharmaceuticals’ Quality Risk Management function.
See the answer from Al Altomari, who is chairman and CEO of Agile Therapeutics and a member of the company’s board of directors.
See the answer from Pamela Contag, Ph.D., the CEO and president of BioEclipse Therapeutics, a clinical-stage, next generation immunotherapy company.
See the answer from Raúl Diaz, who directs MSD Animal Health Large Molecules Biopharm Operations in Montes Claros, Brazil.
Get the latest articles from Life Science Leader delivered to your inbox.